Provided are an optimized fusion protein which comprises N-terminal truncated TACI (transmembrane activator and CAML-interactor) extracellular region and Fc, a DNA sequence encoding the fusion protein, a vector and host cell comprising the DNA sequence, a pharmaceutical composition comprising the fusion protein. A preparing method and use of the fusion protein for treating diseases are also provided.
